9823 Capital’s iRadimed IRMD Stock Holding History

9823 Capital’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,703	Closed	-$263K	–	61
2025 Q4	$263K	Buy	+2,703	New	+$232K	0.18%	33

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

9823 Capital's IRMD Position: Q1 2026 in Review

9823 Capital sold out of iRadimed (IRMD) in Q1 2026, closing a stake of 2,703 shares — an estimated $263K sold.

9823 Capital first reported a position in IRMD in Q4 2025 and held it in 1 quarter. The position peaked at $263K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

9823 Capital reported no remaining iRadimed position as of Q1 2026 after selling out during the quarter.
9823 Capital sold 2,703 iRadimed shares in Q1 2026, an estimated $263K.
9823 Capital first reported a position in iRadimed in Q4 2025 and held it in 1 quarter.
9823 Capital's iRadimed position peaked at $263K in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on 9823 Capital's 13F filing for Q1 2026, filed 15 May 2026.